If an isolate shows elevated fluconazole MIC or has a documented ERG11 resistance allele, clinicians should consider switching to or initiating therapy with an echinocandin for invasive disease and consult infectious-disease specialists for complex cases.
For non-invasive mucosal disease, therapy should be individualized using susceptibility data, with awareness that ERG11 mutations reduce the probability of success with standard fluconazole regimens.

Comments

Popular posts from this blog

Fungi - Candida albicans - Telomere Research Descriptive Posts - Post 6

Fungi - Candida auris - Non-Elaborate Posts - Post 6

Fungi - Candida albicans - Telomeres Specialized Research Descriptive Posts - Non-Elaborate Posts - Post 1